Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration

American Journal of Ophthalmology

Volumn 157, Issue 4, 2014, Pages

  Holekamp, Nancy M ^a   Liu, Ying ^b   Yeh, Wei Shi ^b   Chia, Yifeng ^b   Kiss, Szilárd ^c   Almony, Arghavan ^d   Kowalski, Jonathan W ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Carolina Eye Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BILLING AND CLAIMS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONITORING; NEOVASCULARIZATION (PATHOLOGY); OPHTHALMOLOGIST; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INSURANCE CLAIM REVIEW; INTRAVITREAL INJECTIONS; MALE; MEDICARE PART B; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84896067779     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.12.018     Document Type: Article

References (33)

1. N. Congdon, B. O'Colmain, and C.C. Klaver et al. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 4 2004 477 485
2. B. Muñoz, S.K. West, and G.S. Rubin et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study Arch Ophthalmol 118 6 2000 819 825
3. M. Kliffen, H.S. Sharma, C.M. Mooy, S. Kerkvliet, and P.T. de Jong Increased expression of angiogenic growth factors in age-related maculopathy Br J Ophthalmol 81 2 1997 154 162
4. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 6 2003 669 676
5. J.Y. You, H. Chung, and H.C. Kim Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography Curr Eye Res 37 5 2012 438 445
6. D.R. Lally, A.T. Gerstenblith, and C.D. Regillo Preferred therapies for neovascular age-related macular degeneration Curr Opin Ophthalmol 23 3 2012 182 188
7. S.S. Vedula, and M.G. Krzystolik Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration Cochrane Database Syst Rev 2 2008 CD005139
8. A.L. Takeda, J. Colquitt, A.J. Clegg, and J. Jones Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review Br J Ophthalmol 91 9 2007 1177 1182
9. J.L. Colquitt, J. Jones, S.C. Tan, A. Takeda, A.J. Clegg, and A. Price Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation Health Technol Assess 12 16 2008 iii-iv, ix-201
10. A. Tufail, P.J. Patel, C. Egan ABC Trial Investigators Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study BMJ 340 2010 c2459
11. CATT Research Group D.F. Martin, and M.G. Maguire et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 363 20 2011 1897 1908
12. Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Research Group D.F. Martin, and M.G. Maguire et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
13. IVAN Study Investigators U. Chakravarthy, and S.P. Harding et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 7 2012 1399 1411
14. P.J. Rosenfeld, D.M. Brown, J.S. Heier for the MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
15. D.M. Brown, P.K. Kaiser, M. Michels for the ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
16. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 4 2007 566 583
17. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 5 2011 831 839
18. D.S. Boyer, J.S. Heier, D.M. Brown, S.F. Francom, T. Ianchulev, and R.G. Rubio A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 9 2009 1731 1739
19. C.D. Regillo, D.M. Brown, and P. Abraham et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2 2008 239 248
20. U. Chakravarthy, S.P. Harding, C.A. Rogers on behalf of the IVAN study investigators Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomised controlled trial Lancet 382 9900 2013 1258 1267
21. B.G. Busbee, A.C. Ho, D.M. Brown HARBOR Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 5 2013 1046 1056
22. D.S. Fong, P. Custis, J. Howes, and J.W. Hsu Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study Ophthalmology 117 2 2010 298 302
23. Hansen LG, Chang S. Health research data for the real world: the MarketScan databases. Available at http://www.truvenhealth.com/assets/2012- Truven-MarketScan-white-paper.pdf. Accessed September 25, 2013.
24. T. Rotsos, P.J. Patel, F.K. Chen, and A. Tufail Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration Clin Ophthalmol 4 2010 1271 1275
25. T. Bandukwala, R.H. Muni, C. Schwartz, K.T. Eng, and P.J. Kertes Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review Can J Ophthalmol 45 6 2010 590 595
26. American Society of Retina Specialists (ASRS). Annual preferences and trends survey, 2011. Available (with membership) at http://www.asrs.org/asrs- community/pat-survey. Accessed September 25, 2013.
27. American Society of Retina Specialists (ASRS). Annual preferences and trends survey, 2012. Available (with membership) at http://www.asrs.org/asrs- community/pat-survey. Accessed September 25, 2013.
28. C.A. Cleary, D. Sharaznayan, and M. Hickey-Dwyer Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke Ir Med J 104 5 2011 146 149
29. S. Day, K. Acquah, P. Mruthyunjaya, D.S. Grossman, P.P. Lee, and F.A. Sloan Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration Am J Ophthalmol 152 2 2011 266 272
30. C. Costagliola, L. Agnifili, and B. Arcidiacono et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration Expert Opin Biol Ther 12 10 2012 1299 1313
31. P. Mitchell A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab Curr Med Res Opin 27 7 2011 1465 1475
32. M.A. Singer, C.C. Awh, and S. Sadda et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 6 2012 1175 1183
33. A.R. Shah, and L.V. Del Priore Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements Br J Ophthalmol 93 8 2009 1027 1032